Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis
Abdominal Radiology · 28.07.2026
DOI: 10.1007/s00261-026-05681-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, online erschienen am 28.07.2026. Verfasst von Jianwei Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Ca…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Fujian Provincial Health Technology Project, National Key Research and Development Program of China, Joint Funds for the Innovation of Science and Technology, Fujian ProvinceJoint Funds for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Background
To evaluate treatment response and identify factors associated with outcomes in previously treated hepatocellular carcinoma (HCC) patients receiving Y-90 radioembolization combined with targeted therapy and immunotherapy (Y-90 + TT + IT).
Methods
This retrospective study included 30 previously treated HCC patients (11 with prior surgery, 19 without) who received Y-90 + TT + IT. At a median follow-up of 9.7 months (95% CI, 8.5–13.9), 23 PFS events and 9 overall survival (OS) events occurred. Patient‑level response was assessed in 24 patients (all with PFS events or > 6‑month follow‑up without progression). Univariable Cox regression was used for PFS and OS; owing to few OS events ( n = 9), OS analyses were exploratory. For PFS, an exploratory multivariable model (backward stepwise) was also constructed.
Results
Objective response rate was 37.5% (9/24) and disease control rate 75.0% (18/24); infiltrative imaging appearance was the only feature associated with non‑response ( p = 0.042). Prior surgery was associated with worse PFS in both patient-level (HR 3.78, p = 0.004) and lesion-level (HR 3.32, p = 0.024) analyses; however, the lesion-level association was not confirmed in a sensitivity analysis restricted to one index lesion per patient ( p = 0.128) and should be interpreted cautiously as it may reflect within‑patient clustering. Prior surgery remained significant in multivariable analysis ( p = 0.004). In univariable analysis for OS, total bilirubin ( p = 0.019), lesion number ( p = 0.022), gamma-glutamyl transferase (GGT; p = 0.041), and tumor-to-normal liver uptake ratio (TNR; p = 0.008) were associated with OS.
Conclusions
In this exploratory cohort of previously treated HCC patients receiving Y-90 + TT + IT, prior surgery was associated with worse patient‑level PFS. Infiltrative imaging appearance was associated with non‑response. In univariable analysis, GGT, TNR, total bilirubin, and lesion number showed exploratory associations with OS. These findings generate hypotheses and require validation in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China.
- Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China.
- Department of Interventional Radiology, Xiangyang Central Hospital, Hubei, China.
- Department of Interventional Vascular Surgery, The First Hospital of Putian City, Putian, China.
- Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, China. ztfang…
- Department of Interventional Radiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China. ztfang@fjzlhospital.com.
ORCID-Profile: Zhuting Fang
Förderung
- Fujian Provincial Health Technology Project
- National Key Research and Development Program of China
- Joint Funds for the Innovation of Science and Technology, Fujian ProvinceJoint Funds for the Innovation of Science and Technology, Fujian Province
- Joint Funds for the Innovation of Science and Technology, Fujian Province
- Fujian Province Natural Science Foundation of China
Zitieren
APA
Chen, J., Wang, X., Li, X., Chen, Q., Zhu, Y., Zheng, D., Wen, L., Wu, J., Hu, Y., Chen, S., Hao, M., Yu, W., & Fang, Z. (2026). Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05681-0
Vancouver
Chen J, Wang X, Li X, Chen Q, Zhu Y, Zheng D, et al. Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05681-0
BibTeX
@article{Chen2026,
author = {Chen, Jianwei and Wang, Xiaolong and Li, Xiaoqi and Chen, Qihong and Zhu, Yuemin and Zheng, Dechun and Wen, Liting and Wu, Juyi and Hu, Yubin and Chen, Shiguang and Hao, Mingzhi and Yu, Wenchang and Fang, Zhuting},
title = {Prognostic factors and treatment response in previously treated hepatocellular carcinoma patients receiving Y-90 radioembolization combined with targeted-immunotherapy: an exploratory analysis},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05681-0}
}
EUVIMED